IMF Videos Search Content For Healthcare Professional (76) Healthcare Provider (75) Care Partner (65) Patient (65) Series - Any - ASCO/EHA (31) ASH (30) Ask Dr. Durie (16) Community Workshops (3) Emerging Therapies (12) Facebook Live (6) Health Equity (4) IMWG (3) Living Well with Myeloma (3) Myeloma in a Minute (2) Myeloma Made Simple (6) Myeloma University (9) Q&A (6) Recent News and Developments (2) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (88) High-Risk Myeloma (38) High-risk Smoldering Myeloma (17) Late Relapse (4–6 Lines of Therapy) (101) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (24) Smoldering Myeloma (13) Types of Therapy Immunomodulatory drugs (IMiDs) (31) Immunotherapies (CAR T; BiTE, etc.) (97) Monoclonal antibodies (33) Proteasome inhibitors (23) Stem cell transplant (24) Steroids (20) Supportive Care (36) Year Published 2026 (18) 2025 (22) 2024 (35) 2023 (39) 2022 (4) 2021 (4) 2020 (3) 2019 (2) 2018 (1) 2017 (1) 2016 (4) 2015 (2) Trusted Voices Dr. Joseph Mikhael (35) Dr. Brian GM Durie (15) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Donna Catamero, ANP-BC, OCN, CCRC (3) Dr. María-Victoria Mateos (2) Dr. Saad Usmani (2) Dr. Sagar Lonial (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Bispecifics Part 3: The Pros and Cons of Bispecifics January 13, 2023 Emerging Therapies Bispecifics Part 2: Monoclonal and Bispecific Antibodies January 13, 2023 Emerging Therapies Bispecifics Part I: Immune System and Immunotherapy Basics January 13, 2023 Emerging Therapies Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1/2 Results from MonumenTAL-1 January 12, 2023 ASH KarMMa2: Efficacy and Safety of Idecabtagene Vicleucel in High Risk Multiple Myeloma Pts with Early Relapse after ASCT January 12, 2023 ASH Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple Myeloma January 10, 2023 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD December 22, 2022 ASH What should care providers of myeloma patients know about CAR T-cell therapy? August 11, 2022 Ask Dr. Durie 2nd M-Power Charlotte Community Workshop June 25, 2022 Health Equity A Promising Future for Treating Multiple Myeloma with Bispecific Antibodies June 23, 2022 Living Well with Myeloma M-Power Atlanta Community Workshop November 16, 2021 Health Equity M-Power Baltimore Community Workshop September 21, 2021 Health Equity Load More
